Tirzepatide dosing on TikTok: what the science actually says

What did @chaseveryday actually say?

The creator laid out the FDA-approved tirzepatide dose escalation schedule, then pivoted to compounded versions, claiming you can "customize those doses and make them smaller." They also drew a distinction between milligrams and units, saying milligrams represents strength while units represents volume.

The dose schedule they cited, 2.5 mg starting, escalating through 5, 7.5, 10, 12.5, and up to 15 mg, is accurate and matches the prescribing information for Zepbound and Mounjaro. The compounding flexibility claim is more complicated, and the milligrams-versus-units explanation, while well-intentioned, contains a real conceptual error worth unpacking.

Does the science back this up?

The dose escalation schedule is well-established. Yes, the FDA-approved titration for tirzepatide is exactly what they described, starting at 2.5 mg weekly and stepping up every four weeks as tolerated.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) confirmed that slower titration reduces gastrointestinal side effects without meaningfully compromising efficacy. That trial enrolled over 2,500 adults with obesity and showed that patients who tolerated the escalation protocol saw up to 22.5% body weight reduction at the highest dose. The idea that finer dose increments for GI-sensitive patients has clinical logic behind it, since tolerability drives adherence. However, there is no peer-reviewed evidence specifically validating custom sub-2.5 mg compounded tirzepatide steps like "2.5 to 3 mg" as a formal protocol. That is practitioner judgment, not an established standard of care.

What did they get wrong (or right)?

The milligrams-versus-units explanation is the part that needs a correction. The creator says milligrams is "how strong the medicine is" and units is "how much of it, the volume." That framing is misleading in a clinical context.

Milligrams is a unit of mass, not potency. It tells you how much drug substance is present. "Strength" in pharmacology refers to concentration, typically expressed as milligrams per milliliter (mg/mL). Units, in the context of injectable medications like insulin, is a completely separate standardized measurement system, not interchangeable with volume. Volume is measured in milliliters. For tirzepatide specifically, prescriptions are written in milligrams, not units, so introducing the units concept here adds confusion rather than clarity. If a patient sees a compounded tirzepatide prescription written as mg/mL and tries to convert using the logic presented here, they could make a dosing error. The dose escalation content, however, deserves credit. It is accurate and the GI tolerability rationale for slower titration is clinically sound.

What should you actually know?

If you are on compounded tirzepatide, the concentration of your vial matters as much as the dose on your prescription. These are not the same thing, and confusing them is how dosing errors happen.

Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to brand-name Zepbound or Mounjaro. The FDA has issued guidance on this distinction. Compounding pharmacies operate under different regulatory frameworks, and quality control varies. The flexibility to titrate more gradually can have real value for patients with significant GI sensitivity, but that titration should be directed by a licensed prescriber with clinical oversight, not self-adjusted based on social media content. A 2023 analysis by Rubino et al. in Nature Medicine noted that adherence at 12 months in GLP-1 trials was substantially improved when side effect management was proactive. Slower titration is one tool in that. Always confirm with your provider whether your prescription is written in mg or mg/mL, and clarify the exact volume you should inject at each dose step.